# Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia

> **NCT01351610** · PHASE1,PHASE2 · COMPLETED · sponsor: **Apceth GmbH & Co. KG** · enrollment: 25 (actual)

## Conditions studied

- Critical Limb Ischemia
- Peripheral Artery Disease

## Interventions

- **BIOLOGICAL:** PTA + Infusion of MSC_Apceth
- **PROCEDURE:** PTA

## Key facts

- **NCT ID:** NCT01351610
- **Lead sponsor:** Apceth GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-10
- **Final completion:** 2015-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01351610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01351610, "Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01351610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*